Inflammatory Bowel Disease Clinical Trial
Official title:
Comparison of Immune Response to the Human Papillomavirus Vaccine in Young Women With and Without Inflammatory Bowel Disease
The Gardasil vaccine, a vaccine targeted towards the human papillomavirus (HPV), has been shown to prevent the transmission of several strains of HPV in young women. Women with inflammatory bowel disease (IBD) may not respond as well to this vaccine, either due to having IBD or due to immunosuppressants used to control IBD. This study will test how well women with IBD respond to the Gardasil vaccine.
Although guidelines exist for immunization of patients with inflammatory bowel disease, few
studies exist demonstrating vaccine efficacy in this population. In patients with
inflammatory bowel disease, lower than normal humoral responses have been shown with the
tetanus toxoid booster, oral cholera, and influenza vaccinations. It is currently uncertain
whether women with inflammatory bowel disease (IBD) have an increased risk of cervical
dysplasia and cancer. Gardasil, a vaccine against human papilloma viruses (HPV) 6, 11, 16,
and 18, has been approved for the prevention of cervical dysplasias and cancers in women
ages 9-26 years. However, its immune response in immunocompromised or immunosuppressed
patients is unknown.
Young women with inflammatory bowel disease who have not received the HPV vaccine will
receive the vaccine. The vaccine is given in 3 doses over 6 months. Response to the vaccine
will be measured 6 months after completing the vaccine series.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT03278912 -
Natural History of Intestinal Inflammation in People With Primary Immune Dysregulations
|
||
Terminated |
NCT00061282 -
Clotrimazole Enemas for Pouchitis in Children and Adults
|
Phase 1/Phase 2 | |
Recruiting |
NCT05579392 -
A Randomized Crossover Trial of Bright Light Therapy in Crohn's Disease on Intestinal Barrier Homeostasis
|
N/A | |
Completed |
NCT03264690 -
Study to Observe the Change in Microbiome in Human Derived Sample and the Relation With Clinical Response Before and After the Anti-TNF Treatment in IBD Patients
|
||
Recruiting |
NCT02861053 -
Inflammatory Bowel Disease : Could a Regular Physical Activity Reduce Patients Fatigue ?
|
N/A | |
Recruiting |
NCT02275676 -
Resting Energy Expenditure and Nutritional Status in IBD
|
N/A | |
Completed |
NCT02161640 -
Vascular Dysfunction in Paediatric IBD
|
N/A | |
Completed |
NCT02197780 -
Head-to-head Comparison of Two Fecal Biomarkers to Screen Children for IBD
|
N/A | |
Completed |
NCT02503696 -
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
|
N/A | |
Completed |
NCT01852760 -
Assessment of Disease Activity in Ulcerative Colitis by Endoscopic Ultrasound
|
N/A | |
Completed |
NCT01933867 -
Water-aided Colonoscopy in Inflammatory Bowel Disease Patients
|
N/A | |
Completed |
NCT01860651 -
Web-based Monitoring in Children and Adolescents With Inflammatory Bowel Disease
|
N/A | |
Completed |
NCT01666535 -
Infliximab IBD Influenza Vaccine Study
|
N/A | |
Completed |
NCT01676324 -
FOCUS: The Future of Fecal Calprotectin Utility Study for the Diagnosis and Management of Inflammatory Bowel Disease (IBD)
|
N/A | |
Completed |
NCT01688557 -
Trial on Innovative Technologies in Colonoscopy
|
N/A | |
Completed |
NCT01692743 -
Telemedicine in Patients With Inflammatory Bowel Disease (TELE-IBD)
|
Phase 3 | |
Completed |
NCT01557387 -
Real-time Diagnosis of Pseudopolyps During Colonoscopy
|
||
Completed |
NCT01981616 -
Immune Response to Systemic and Mucosal Antigenic Challenge in the Presence of Vedolizumab
|
Phase 1 | |
Completed |
NCT01221818 -
A Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study of E6007 in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01476995 -
Prognostic Indicators as Provided by the EPIC ClearView
|
N/A |